Telomerase reverse transcriptase promoter mutation and its clinical implication in thyroid cancer
Jae Hoon Chung
Precis Future Med. 2018;2(1):8-17.   Published online 2018 Mar 30     DOI: https://doi.org/10.23838/pfm.2018.00016
Citations to this article as recorded by Crossref logo
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‚Äźanalysis
Bojie Chen, Yuan Shi, Yanan Xu, Jing Zhang
Clinical Endocrinology.2021; 94(5): 731.     CrossRef
Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1 Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
Thyroid.2020; 30(11): 1589.     CrossRef
BRAF and TERT promoter mutations: clinical application in thyroid cancer
Jae Hoon Chung
Endocrine Journal.2020; 67(6): 577.     CrossRef